Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
Summary
Reporting to the Vice President, Investor Relations and Corporate Communications, we are hiring a strategic communicator to oversee Product and Pipeline Communications for vopimetostat, our lead PRMT5 inhibitor, and other oncology pipeline candidates. This is an opportunity to create and deliver communications programs in support of clinical data, development efforts, and potential patient benefits.
Your role
- Lead communications for vopimetostat, covering data, regulatory milestones, and commercial launch
- Develop cross-functional messaging
- Execute disease awareness, branded campaigns, integrations, and digital/social media initiatives
- Partner with Clinical Development and Operations team to support clinical trial communications, including development of digital assets
- Collaborate with Clinical Development, Medical Affairs, Patient Advocacy, Regulatory, Legal, IR, Internal Communications, and external partners
- Represent the function on integrated teams and contribute to business decisions
- Support executive engagement through media, speaking opportunities, and internal communications
- Manage issues proactively to protect reputation; use analytics to assess communication strategies
What You Bring
- Bachelor’s degree with 10 plus years of experience in public relations or communications within the pharmaceutical or biotech industry
- Strong understanding of oncology drug development, regulatory policy, medical meeting and publications strategy
- Expertise in issues management within drug development
- Ability to adapt quickly in fast-changing environments
- Demonstrated success working in cross-functional, matrixed teams with an enterprise approach
- Preferred qualifications: Public relations or communications experience in oncology
This is a Hybrid/Flexible role!
#LI-Hybrid
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
#LI-Hybrid
Skills Required
- Bachelor's degree
- 10 plus years of experience in public relations or communications within the pharmaceutical or biotech industry
- Strong understanding of oncology drug development, regulatory policy, medical meeting and publications strategy
- Expertise in issues management within drug development
- Ability to adapt quickly in fast-changing environments
- Demonstrated success working in cross-functional, matrixed teams
- Public relations or communications experience in oncology
What We Do
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
